Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observational Study of Canadian Patients Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

NCT06099704 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06099704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06099704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observational Study of Canadian Patients Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
Lead sponsor
Sanofi
Phase
Observational
Overall status
Completed
Start date
October 10, 2023
Completion date
April 14, 2026
Enrollment
305 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe atopic dermatitis